Concise Prescribing Info
Management of schizophrenia & treatment of moderate to severe mania associated w/ bipolar disorders.
Dosage/Direction for Use
Schizoprenia 10 mg/day. Manic episode 15 mg as single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence in bipolar disorder 10 mg/day, max of 20 mg/day. Elderly 5 mg/day. Renal &/or hepatic impairment 5 mg/day.
May be taken with or without food.
Hypersensitivity. Narrow-angle glaucoma.
Special Precautions
Dementia-related psychosis &/or several behavioural disturbances. Cerebrovascular adverse events eg, stroke, transient ischaemic attack. Patients w/ Parkinson's disease. Neuroleptic malignant syndromes. Observe signs & symptoms of hyperglycemia eg, polydipsia, polyuria, polyphagia & weakness. Monitor & control glucose regularly for patients w/ DM. Undesirable alterations of lipids. Patients w/ prostatic hypertrophy or paralytic ileus. Discontinue if hepatitis occurs. Neutropenia; thromboembolism. Avoid abrupt w/drawal. Drugs known to increase QTc interval. Centrally-acting drugs & alcohol. Patients w/ history of seizure. Discontinue treatment if symptoms of tardive dyskinesia appear. Periodically monitor & measure BP. Sudden cardiac death. May affect ability to drive & use of machinery. Pregnancy & lactation. Childn & adolescents.
Adverse Reactions
Wt gain; somnolence; elevated plasma prolactin levels. Eosinophilia, leukopenia, neutropenia; elevated cholesterol levels, elevated glucose levels, elevated triglyceride levels, glucosuria, increased appetite; sedation; dizziness, akathisia, parkinsonism, dyskinesia; orthostatic hypotension; mild transient anticholinergic effects including constipation & dry mouth; transient asymptomatic elevations of hepatic aminotransferase (ALT, AST); rash; asthenia; fatigue; pyrexia; arthralgia; erectile dysfunction in males; increased alkaline phosphatase; high gamma glutamyltransferase; high uric acid; high creatine phosphokinase & oedema; decreased total bilirubin, increased GGT & elevated plasma prolactin levels.
Drug Interactions
Reduced conc w/ smoking & carbamazepine. Inhibition of metabolism w/ fluvoxamine. Decreased bioavailability w/ activated charcoal. May antagonize effect of direct & indirect dopamine agonists. CNS depression w/ alcohol. Antiparkinsonian drugs & products known to increase QTc interval.
MIMS Class
ATC Classification
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics
Olanpresor tab 10 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in